Evidence map›Paper›PMID 41795704›Full record

ArticleActa ophthalmologica2026

The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy (OMEGA) study: Geographic atrophy progression in fundus autofluorescence - OMEGA report 3.

Philippe Valmaggia, Georg Ansari, Nadja Inglin, Nils Schärer, Hanna Zuche, Chrysoula Gabrani, Faady Yahya, Marco Cattaneo, Kristina Pfau, Andrea Giani and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Philippe ValmaggiaDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0003-2817-5630
Georg AnsariDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0008-4693-2061
Nadja InglinDepartment of Biomedical Engineering, University of Basel, Allschwil, Switzerland.
Nils SchärerDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0002-7218-1659
Hanna ZucheDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0003-0849-4976
Chrysoula GabraniDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0003-7710-6671
Faady YahyaDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.
Marco CattaneoInstitute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.ORCID https://orcid.org/0000-0002-6610-8431
Kristina PfauDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-3642-3502
Andrea GianiBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Marieh EsmaeelpourBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Taffeta Chingning YamaguchiBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Christian PrünteDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-8405-8933
Hendrik P N SchollPallas Kliniken AG, Pallas Klinik Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-7312-0316
Nicolas FeltgenDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-6857-3003
Leopold SchmettererDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-7189-1707
Maximilian PfauDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-9761-9640
Peter M MalocaDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-4794-5859

Funding

Boehringer Ingelheim Pharma GmbH & Co. KGSchweizerische Akademie der Medizinischen Wissenschaften YTCR 43/23Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 323530_199395
6 · The paper itself

Abstract

purposeTo measure the progression of geographic atrophy (GA) in subjects with age-related macular degeneration (AMD) in a natural history study.

methodsWe analysed fundus autofluorescence (FAF) images using a semiautomatic method (RegionFinder) to quantify the GA area in a monocentric study. Three independent graders analysed each eye. Patient visits were scheduled at baseline, 12, 24 and 48 weeks. The primary endpoint was the progression of GA area per eye. Potential correlations with clinical and imaging-based parameters were analysed.

resultsThe annual GA progression rate was 1.16 mm

conclusionGA progression in AMD is significantly influenced by baseline lesion size and a larger number of smoking pack-years is associated with larger GA lesions. The marked variability between individuals underscores the multifactorial nature of GA dynamics. Quantitative FAF analysis is a reliable method for assessing lesion progression and may inform risk-based monitoring strategies.

Indexed as

Fluorescein AngiographyGeographic AtrophyRetinal Pigment EpitheliumTomography, Optical CoherenceVisual AcuityVisual FieldsVisual Field TestsAgedAged, 80 and overBiomarkersDisease ProgressionFemaleFollow-Up StudiesFundus OculiHumansMaleBiomarkersage‐related macular degenerationdisease progressionfundus autofluorescencegeographic atrophynatural history

Identifiers

PMID41795704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.